

WNW

DILUTION MACHINE

Meiwu Technology

premarket movers

acquisition

small-cap

dilution risk

China stocks

NASDAQ

WNW Gaps 30% Premarket on \$35M Acquisition Filing — and the Fine Print Raises a Financing Question

August 27, 2026 — 8:38 AM EDT · Report #107 · Free Equity Reports Research

◆ DESK TAKE

Gapped ~30% premarket August 27 on an August 26 6-K: a ~\$35M cash agreement to buy Xiamen Hemeitong, third-party appraisal attached — after 12M+ shares churned flat on Wednesday. Supply is the story: March's \$2.00 warrants carry a zero-exercise option worth up to 12 shares each and are deep in the money, so rips can meet paper. Watch \$4.50 premarket-high resistance and \$3.25 support into the open; below \$3.25 the \$2.48 prior close is the magnet.


DATA BOX

Price	\$3.22
Change	+29.75%
Volume	5.99M
Float	26.20M
Mkt cap	\$84.73M

MECHANICS

Roughly 26.3M shares outstanding with nearly the entire count in the float. March 2026 registered direct attached ~7M one-year warrants at \$2.00 with a zero-exercise option paying up to 12 shares per warrant cashlessly; an F-3 shelf went effective February 24, 2026, and a \$15.65M PIPE followed in May. The company executed a 1-for-20 reverse split in April 2025 (52-week range \$2.25–\$1,352 reflects cumulative consolidations) and holds a September 14, 2026 EGM to vote on a dual-class share structure.

WNW — PRIOR SESSION → REPORT TIME



DATA BOX — MACHINE-VERIFIED

Data Box — WNW · as of 8:36 AM ET, 2026-08-27 · Pre-market session

METRIC	VALUE
Price	\$3.22
Previous close	\$2.48
Change	+29.75%
Volume (premarket)	5.99M
Float	26.20M
Shares outstanding	26.33M
Market cap	\$84.73M
52-week range	\$2.25 - \$1,352.00
Avg daily volume (20d)	705.7K
Relative volume	N/A (premarket)

All figures machine-sourced from market data APIs at publication time.

Meiwu Technology (NASDAQ: WNW) is trading up roughly 30% in Thursday's premarket, as of this writing at 8:36 AM ET on August 27. The tape actually tipped its hand a day early: Wednesday August 26, WNW

churned over 12 million shares — against a recent daily norm in the tens of thousands — while closing nearly flat at \$2.48. Somebody moved a lot of stock before the price did. This morning the gap arrived, tagging the mid-\$4s early before fading back toward the low-\$3s, below the premarket VWAP. That's the second run we've covered this year; our March 16 report caught the 570% AI-initiative spike from \$2.15.

The catalyst on file

A 6-K hit EDGAR dated August 26. Meiwu signed an agreement with two shareholders of Xiamen Hemeitong to acquire 100% of its equity, agreeing to pay an aggregate of RMB23,520,000 — which the filing calls “approximately \$35,000,000” — in cash at closing. Flag the arithmetic: RMB 23.52 million converts to roughly \$3.3M, not \$35M, so one of those figures is off by a decimal. The appraisal suggests the dollar number is the intended one — an independent valuation by Beijing Yingyue Asset Appraisal pegged Hemeitong's full equity at RMB 239,405,140, approximately \$35.3M, as of June 30, 2026, and closing remains subject to customary conditions.

Context on the buyer: Meiwu pivoted from online food sales and SMS services into functional skincare, which it now sells through subsidiary Xiamen Chunshang, and spent July cleaning house — shedding a defunct SMS subsidiary on July 9 and disposing of a BVI subsidiary for a nominal sum on July 29.

The financing question

A \$35M cash acquisition from a company this size begs the obvious question: where does the cash come from? Recent history says the capital

markets. In March, Meiwu raised about \$14M selling roughly 7 million shares at \$2.00 in a registered direct, with 1-year warrants for another 7 million shares at \$2.00 attached. Those warrants carry teeth: a “zero exercise price” option letting holders take up to 12 ordinary shares per warrant, cashlessly, anytime while outstanding. That’s a theoretical supply spigot an order of magnitude larger than the float, live into next March, sitting deep in the money this morning. Then a \$15.65M PIPE followed in May to fund the AI skincare platform. There’s also a governance wrinkle on deck: a September 14 extraordinary meeting in Xiamen to vote on a dual-class structure with enhanced voting rights for Class B shares — insider control consolidating just as the deal pipeline heats up.

The levels

The thesis fight is simple. Bulls have a real, filed catalyst with a third-party valuation attached. Bears have warrant supply, a fade off the premarket high, and price sitting under VWAP into the open — sellers winning the early tape. Brackets:

- **\$4.50** — the premarket high; reclaiming it on regular-session volume changes the conversation
- **\$3.25** — the premarket floor; lose it and the \$2.48 prior close is the magnet
- Volume tell: if the open can’t sustain Wednesday-scale turnover, the fade likely continues

Closing details on the Hemeitong deal — and how it’s funded — are the next real data points. Until then, treat every pop as potential exit liquidity for warrant holders and size accordingly.

This is not investment advice; do your own research and manage your own risk.

MECHANICS BOX — THE STRUCTURAL READ

- Shares outstanding: 26.33M · Float: 26.20M
- Dilution-relevant SEC filings (30d): none found in the last 30 days
- Splits: 1-for-100 reverse (2026-04-06), 1-for-20 reverse (2025-04-01), 1-for-35 reverse (2023-12-20)
- Roughly 26.3M shares outstanding with nearly the entire count in the float. March 2026 registered direct attached ~7M one-year warrants at \$2.00 with a zero-exercise option paying up to 12 shares per warrant cashlessly; an F-3 shelf went effective February 24, 2026, and a \$15.65M PIPE followed in May. The company executed a 1-for-20 reverse split in April 2025 (52-week range \$2.25–\$1,352 reflects cumulative consolidations) and holds a September 14, 2026 EGM to vote on a dual-class share structure.

The Setup: This is a [Dilution Machine](#) play — read the pattern guide to learn how these setups typically unfold.

This report is for informational purposes only and does not constitute investment advice. Always conduct your own due diligence before making any investment decision.